Clinical Trial Results for TCM Adjuvant Therapy in Stage IB-IIIA NSCLC

A multi-center, randomized, double-blind, placebo-controlled trial involving 286 patients with completely resected stage IB-IIIA non-small cell lung cancer. The study, conducted at four centers in Shanghai, China, evaluated the efficacy and safety of comprehensive Traditional Chinese Medicine combined with platinum-based adjuvant chemotherapy. Results include 2-year disease-free survival rates, hazard ratios, and quality-of-life symptom improvements.

Use Cases

• Compare disease-free survival outcomes between treatment and control groups based on reported hazard ratios and survival times.
• Analyze the impact of Traditional Chinese Medicine on specific lung cancer-related symptoms like fatigue, pain, and dyspnea.
• Study the safety profile of an adjuvant therapy regimen based on the reported absence of unexpected adverse events.
• Model treatment efficacy in a specific patient population (stage IB-IIIA, R0 resection) based on the trial's inclusion criteria.

Strengths

• Data originates from a registered, multi-center randomized controlled trial (ChiCTR-IPR-16009062).
• Includes results for 286 patients with specific metrics like 2-year DFS rates and median DFS (37.8 vs. 31.6 months).
• Reports on multiple patient-reported outcomes including physical function, emotional function, and overall health.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (37.7 KB), suggesting it contains summary results rather than individual patient-level data.

Provenance

Source

figshare, authored by Liping Shen.

Collection Method

Data likely extracted from the results of a clinical trial.

Time Range

Temporal coverage of the trial is not specified.

Freshness

Last updated 2026-04 07:40:48; freshness should be verified.

Geography

The trial was conducted at four centers in Shanghai, China.